F.D.A. Clears New Cancer-Fighting Drug From Roche

.

F.D.A. Clears New Cancer-Fighting Drug From Roche

A new drug from the drug company Roche has been given the nod by the US Food and Drug Administration (FDA) to improve the treatment of patients suffering from a kind of cancer of the blood and bone marrow.

Roche is calling the new medicine Gazyva which is meant to fight chronic lymphocytic leukemia along with added treatment with chemotherapy. It is meant for those patients who have never before been treated for the same.

Gazyva provides relief in this cancer by destroying cancer cells and enabling the natural immune system of the body to fight against them.

The FDA gave its approval to Gazyva after proof that the drug along with chemotherapy was a better treatment to chemotherapy alone in slowing the progress of the cancer cells.

It was also seen that cancer patients who got treatment from Gazyva combined with chemotherapy had a higher survival rate with 23 months before death, relapse or spreading of the cancer cells.

Earlier treatments treated only with chemotherapy only got 11.1 months.

The new drug Gazyva will be sold by Roche s Genentech unit.


Latest News

Though Wages in Japan Increase But It’s not Enough to Beat Inflation
Jack Ma Prepares for Second Alibaba IPO
RBA Feels Currency Overrated: Keeps Record Low Benchmark Rate
U.S. Business Lobby Express Concerns Saying Antitrust Probes in China Unfair
First dengue fever outbreak in 70 years in Japan
Rise in skin cancer due to cheap holidays
Cardio and wine is a great combination
Surrogacy is a form of exploitation: Ekman
Cuba Trims Down on Amount of Goods Which can be Carried by Travellers
Barclays Will Sell Its Spanish Businesses To CaixaBank In a Deal of 800 Million
Withdrawal in China’s Purchasing Managers' Index Amplifies Calls for Policy Easi
The Ukraine Mayhem Leads Euro to a Fresh One Year Low